Ubiquitin-Activating Enzymes (Ubiquitin-Activating Enzyme)

A class of enzymes that catalyzes the ATP-dependent formation of a thioester bond between itself and UBIQUITIN. It then transfers the activated ubiquitin to one of the UBIQUITIN-PROTEIN LIGASES.

Also Known As:

Ubiquitin-Activating Enzyme; Ubiquitin-Activating Enzyme E1; Ubiquitination Activating Enzyme E1; Enzyme E1, Ubiquitin-Activating; Enzyme, Ubiquitin-Activating; Enzymes, Ubiquitin-Activating; Ubiquitin Activating Enzyme; Ubiquitin Activating Enzyme E1; Ubiquitin Activating Enzymes

Networked: 41 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Berger, Allison: 2 articles (12/2019 - 01/2019)
2.	Best, Scott: 2 articles (12/2019 - 01/2019)
3.	Bruss, Nur: 2 articles (12/2019 - 01/2019)
4.	Danilov, Alexey V: 2 articles (12/2019 - 01/2019)
5.	Kittai, Adam: 2 articles (12/2019 - 01/2019)
6.	Liu, Tingting: 2 articles (12/2019 - 01/2019)
7.	Matsuo, Shingo: 2 articles (01/2018 - 01/2018)
8.	Wang, Ping: 2 articles (01/2018 - 01/2018)
9.	Yang, Weng-Lang: 2 articles (01/2018 - 01/2018)
10.	Alessi, Hugh: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment." 10/01/2007 - "Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics." 10/08/2019 - "The E1-like ubiquitin-activating enzymes (e.g., UBA5) have been recently described as important targets for future treatment of cancer progression, such as leukemia, among others. " 01/01/2024 - "UPP inhibitors, including TAK-243, a first-in-class inhibitor of the E1 ubiquitin-activating enzyme, are currently being used and tested for treatment of a range of diseases, particularly cancer. " 01/01/2021 - "SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243."
2.	Cognitive Dysfunction 09/01/2010 - "The aim of the present study is to explore whether ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, ubiquitin or proteasome activity are affected in peripheral blood mononuclear cells (PBMC) of AD, mild cognitive impairment (MCI) and Parkinson's disease (PD) patients compared to healthy subjects. "
3.	Vaccinia 01/01/2017 - "In this study, we examined the ability of MLN7243, a recently described ubiquitin-activating enzyme E1 inhibitor, to block overall cytosolic peptide generation and generation of specific peptides from vaccinia- and influenza A virus-encoded proteins. "
4.	Parkinson Disease (Parkinson's Disease) 09/01/2010 - "The aim of the present study is to explore whether ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, ubiquitin or proteasome activity are affected in peripheral blood mononuclear cells (PBMC) of AD, mild cognitive impairment (MCI) and Parkinson's disease (PD) patients compared to healthy subjects. "
5.	Inflammation (Inflammations) 11/17/2015 - "Thus our studies reveal a regulatory role for protein ISGylation in colonic inflammation and its related malignant progression, indicating that targeting ubiquitin-activating enzyme E1 homolog has therapeutic potential in treating inflammatory diseases. "

Related Drugs and Biologics

1.	Ubiquitin
2.	Proteasome Endopeptidase Complex (Proteasome)
3.	ATPases Associated with Diverse Cellular Activities
4.	Proteins (Proteins, Gene)
5.	TAK-243
6.	Ubiquitin-Conjugating Enzymes
7.	Peptides (Polypeptides)
8.	Enzymes
9.	Tubulin
10.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Therapeutics